A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed By Maintenance Therapy With the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-risk Hematologic Malignancies
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Ixazomib (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 12 Dec 2017 Planned End Date changed from 1 Jun 2020 to 1 Jul 2020.
- 12 Dec 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2018.
- 29 Feb 2016 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020, according to ClinicalTrials.gov record.